Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 3
2004 5
2005 10
2006 10
2007 17
2008 8
2009 8
2010 8
2011 9
2012 8
2013 27
2014 30
2015 34
2016 48
2017 55
2018 38
2019 50
2020 64
2021 67
2022 59
2023 56
2024 36

Text availability

Article attribute

Article type

Publication date

Search Results

560 results

Results by year

Filters applied: . Clear all
Page 1
Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial.
Coletta AM, Simon LH, Maslana K, Taylor S, Larson K, Hansen PA, Thomas VM, Ulrich CM, Kohli M, Chipman J, Swami U, Gupta S, Maughan BL, Agarwal N. Coletta AM, et al. Among authors: agarwal n. BMC Cancer. 2024 Apr 18;24(1):493. doi: 10.1186/s12885-024-12260-3. BMC Cancer. 2024. PMID: 38637770 Free PMC article.
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens.
Saad E, Gebrael G, Semaan K, Eid M, Saliby RM, Labaki C, Sayegh N, Wells JC, Takemura K, Ernst MS, Lemelin A, Basappa NS, Wood LA, Powles T, Ernst DS, Lalani AA, Agarwal N, Xie W, Heng DYC, Choueiri TK. Saad E, et al. Among authors: agarwal n. Oncologist. 2024 Apr 17:oyae072. doi: 10.1093/oncolo/oyae072. Online ahead of print. Oncologist. 2024. PMID: 38630540 Free article.
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.
Pal SK, Tran B, Haanen JBAG, Hurwitz ME, Sacher A, Tannir NM, Budde LE, Harrison SJ, Klobuch S, Patel SS, Meza L, Dequeant ML, Ma A, He QA, Williams LM, Keegan A, Gurary EB, Dar H, Karnik S, Guo C, Heath H, Yuen RR, Morrow PK, Agarwal N, Srour SA. Pal SK, et al. Among authors: agarwal n. Cancer Discov. 2024 Apr 5:OF1-OF14. doi: 10.1158/2159-8290.CD-24-0102. Online ahead of print. Cancer Discov. 2024. PMID: 38583184
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations.
Gebrael G, Meza L, Li X, Zengin Z, Sayegh N, Ebrahimi H, Tripathi N, Castro D, Mercier B, Barragan-Carrillo R, Li H, Chehrazi-Raffle A, Swami U, Tripathi A, Agarwal N, Maughan BL, Pal SK. Gebrael G, et al. Among authors: agarwal n. Eur Urol Focus. 2024 Apr 4:S2405-4569(24)00050-6. doi: 10.1016/j.euf.2024.03.006. Online ahead of print. Eur Urol Focus. 2024. PMID: 38580524
Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.
George DJ, Agarwal N, Ramaswamy K, Klaassen Z, Bitting RL, Russell D, Sandin R, Emir B, Yang H, Song W, Lin Y, Hong A, Gao W, Freedland SJ. George DJ, et al. Among authors: agarwal n. Prostate Cancer Prostatic Dis. 2024 Apr 2. doi: 10.1038/s41391-024-00815-1. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38565911
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor.
Gebrael G, Jo Y, Mathew Thomas V, Li H, Sayegh N, Tripathi N, Srivastava A, Nordblad B, Dal E, Narang A, Brundage J, Campbell P, Galarza Fortuna G, Hage Chehade C, Maughan BL, Agarwal N, Swami U. Gebrael G, et al. Among authors: agarwal n. Cancer. 2024 Apr 2. doi: 10.1002/cncr.35302. Online ahead of print. Cancer. 2024. PMID: 38564301
Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
Gebrael G, Hage Chehade C, Sayegh N, Tripathi N, Chigarira B, Goel D, Nordblad B, McFarland TR, Narang A, Srivastava A, Tandar C, Dal E, Jo Y, Galarza Fortuna G, Mathew Thomas V, Sahu KK, Li H, Maughan BL, Swami U, Agarwal N. Gebrael G, et al. Among authors: agarwal n. Prostate. 2024 Apr 1. doi: 10.1002/pros.24696. Online ahead of print. Prostate. 2024. PMID: 38561317
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.
Appleman LJ, Kim SE, Harris WB, Pal SK, Pins MR, Kolesar J, Agarwal N, Parikh RA, Vaena DA, Ryan CW, Hashmi M, Costello BA, Cella D, Dutcher JP, DiPaola RS, Haas NB, Wagner LI, Carducci MA. Appleman LJ, et al. Among authors: agarwal n. J Clin Oncol. 2024 Mar 26:JCO2301544. doi: 10.1200/JCO.23.01544. Online ahead of print. J Clin Oncol. 2024. PMID: 38531002
560 results